Table 3.

Univariate analysis of potential factors associated with OS, PFS, LRRFS, and DMFS.

Variables	OS			PFS			LRRFS			DMFS
	Case	5y-(%)	P	Case	5y-(%)	P	Case	5y-(%)	P	Case	5y-(%)	P
Age
≤ 60	327	81.8	0.035	327	76.2	0.054	327	89.4	0.923	327	84.3	0.073
＞60	50	73.6		50	64.3		50	90.7		50	72.5
Gender
Male	266	78.4	0.065	266	71.9	0.112	266	86.6	0.023	266	82.6	0.854
Female	111	85.8		111	80.7		111	96.1		111	83.2
ECOG PS
0	229	85.5	＜0.001	229	80.5	＜0.001	229	90.9	0.095	229	88.5	＜0.001
1-2	148	73.3		148	65.4		148	87.2		148	73.9
BMI
＜18.5	24	79.2	0.664	24	79.2	0.392	24	95.2	0.509	24	83.1	0.328
18.5–24.0	191	79.1		191	72.0		191	88.0		191	80.3
＞24.0	162	82.9		162	77.3		162	90.8		162	85.7
EBV-DNA
＜400	212	86.1	0.011	212	79.9	0.001	212	91.1	0.180	212	88.2	＜0.001
≥400	165	73.9		165	67.8		165	84.0		165	75.8
T stage
1-2	196	85.4	0.003	196	81.6	0.001	196	93.5	0.008	196	87.9	0.009
3-4	181	75.6		181	67.1		181	85.1		181	77.2
N stage
0-1	85	91.4	0.038	85	82.8	0.054	85	95.1	0.121	85	87.0	0.170
2-3	292	77.6		292	72.2		292	87.8		292	81.5
Clinical stage
I-III	283	83.2	0.040	283	76.9	0.030	283	90.2	0.280	283	85.6	0.009
IVa	94	73.1		94	67.8		94	87.6		94	74.5
Treatment
CCRT	121	83.6	0.571	121	79.0	0.370	121	93.0	0.548	121	84.9	0.402
nonCCRT	256	79.3		256	72.5		256	87.8		256	81.9
PIV
Low	129	90.0	0.001	129	82.7	0.005	129	91.2	0.322	129	90.7	0.004
High	248	75.9		248	70.5		248	88.7		248	78.7

OS overall survival, PFS progression free survival, LRRFS local regional recurrence free survival, DMFS distant metastasis free survival, ECOG PS Eastern Cooperative Oncology Group Performance Status, BMI Body Mass Index, CCRT concurrent chemo-radiotherapy, PIV pan-immune-inflammation value.